Clinical Trials
48 trialsTRIDENT-1
Turning Point Therapeutics, Inc.
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
National Institutes of Health Clinical Center (CC)
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Perspective Therapeutics
BRAVESST2
Crinetics Pharmaceuticals Inc.
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Teclison Ltd.
LUPARPED
Fundación de investigación HM
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
National Health Research Institutes, Taiwan
GoTHAM
Melanoma and Skin Cancer Trials Limited
MK-6070-001
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Chimeric Therapeutics
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
Open-label Study of Surufatinib in Japanese Patients
Hutchmed
Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET
National Health Research Institutes, Taiwan
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
ARROW
Hoffmann-La Roche
61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)
University Hospital, Basel, Switzerland
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
AHS Cancer Control Alberta
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
FETONET
Imperial College London
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors
Peking Union Medical College Hospital
18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies
Memorial Sloan Kettering Cancer Center
LuX
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
RADNET
Uppsala University
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe, Inc.
An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
SPORE-3
University of Iowa
68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours
Medical University Innsbruck
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
Ipsen
PLANET
Duke University
REGOMUNE
Institut Bergonié
PET
Peking Union Medical College Hospital
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Tarveda Therapeutics
GA-68
University of Iowa
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
University of Iowa
DEBOXA for Inoperable NET Liver Metastases
Xiangya Hospital of Central South University
DOTA-TOC
University of California, San Francisco
Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas
University of Maryland, Baltimore
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
Ipsen
[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
AHS Cancer Control Alberta
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
Arbutus Biopharma Corporation
Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue
King Faisal Specialist Hospital & Research Center
A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms
Xiangya Hospital of Central South University
GaIN
Insel Gruppe AG, University Hospital Bern
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Ochsner Health System
Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
Guangdong Provincial People's Hospital